Compare Boston Scientific Corporation (BSX) vs Freeport-McMoRan Inc (FCX) Price & Performance

Boston Scientific (BSX) trades at $51.69, up 0.98% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows strong fundamentals with Q2 2026 EPS of $0.86 beating estimates and revenue growth to $20.07B in 2025, alongside improving net income margins. Analyst sentiment is overwhelmingly positive with 86% buy ratings and a $67.21 consensus price target, though recent news highlights guidance cuts and competitive pressures in key segments like WATCHMAN.

The stock presents a compelling long-term opportunity given robust earnings growth and institutional confidence, but faces near-term risks from execution challenges and market volatility. Upside potential exists if the company stabilizes guidance and leverages new product catalysts, making it attractive for investors with a tolerance for sector-specific headwinds.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.